Mesenchymal stem cells therapy for the treatment of non-union fractures: a systematic review and meta-analysis
Cunbao Cui,
No information about this author
Feng Lin,
No information about this author
Liang Xia
No information about this author
et al.
BMC Musculoskeletal Disorders,
Journal Year:
2025,
Volume and Issue:
26(1)
Published: March 12, 2025
Abstract
Background
This
meta-analysis
aimed
to
pool
the
existing
evidence
determine
clinical
efficacy
and
safety
of
mesenchymal
stem
cells
(MSC)
in
patients
with
non-unions.
Methods
A
systematic
search
PubMed
Scopus
was
performed
until
October
2024
gather
pertinent
studies.
The
inclusion
criteria
included
participants
non-unions,
intervention
MSC
administration,
a
comparator
standard
treatment
(bone
graft),
outcomes
focused
on
healing
rate,
time,
or
side
effects.
Jadad
score
Newcastle-Ottawa
Scale
(NOS)
used
assess
risk
bias
randomized
non-randomized
studies,
respectively.
Moreover,
GRADE
were
quality
evidence.
Using
random
effects
model,
odds
ratios
(OR)
95%
confidence
intervals
(CIs)
calculated
for
complication
rates,
while
standardized
mean
differences
(SMD)
their
CIs
impact
therapy
bone
union
time.
Results
Twenty-one
866
patients,
included.
rates
44%
at
3
months,
73%
6
90%
9
86%
12
eventually
reaching
91%
after
months
follow-up.
therapy,
without
scaffolds,
linked
higher
rate
compared
grafts
as
care
(OR
=
1.69).
time
following
6.30
(95%CI:
86-96%),
treated
MSC/Scaffold
experiencing
shorter
alone
(5.85
vs.
6.36
months).
significantly
decreased
(SMD:-0.54
CI:
-0.75
-0.33).
1%
(MSC/Scaffold:
0%,
alone:
2%),
showing
lower
than
0.41,
0.22–0.78).
Conclusion
is
potential
adjunct
non-union
fractures.
Clinical
trial
number
Not
applicable.
Language: Английский
Harnessing stem cell therapeutics in LPS-induced animal models: mechanisms, efficacies, and future directions
Chengran Wang,
No information about this author
Fanghong Ge,
No information about this author
Fenfen Ge
No information about this author
et al.
Stem Cell Research & Therapy,
Journal Year:
2025,
Volume and Issue:
16(1)
Published: April 12, 2025
The
severity
and
threat
posed
by
inflammation
are
well
documented,
lipopolysaccharides
(LPS),
as
important
inducers
of
inflammatory
responses,
widely
recognized
for
studying
host
immunity
the
resulting
tissue
organ
damage.
LPS-induced
disease
model,
triggers
a
remarkable
release
factors,
immune
coagulation
dysfunction,
damage
to
vital
organs
such
brain,
lungs,
heart,
liver,
kidneys.
Recently,
role
mesenchymal
stem
cells
(MSCs)
in
various
clinical
diseases
has
garnered
significant
attention
due
their
immunomodulatory,
anti-inflammatory,
healing,
anti-apoptotic,
antibacterial
properties.
Despite
common
use
LPS
models
induce
simulate
acute
inflammation,
integration
cell
therapy
within
these
remains
underexplored.
This
article
integrates
induced
animal
model
reviews
current
evidence
regarding
therapeutic
mechanisms
across
human
body
systems.
Furthermore,
this
review
predicts
hypothesizes
feasibility
potential
using
that
have
not
yet
been
extensively
studied,
based
on
existing
models.
Language: Английский